Role of endothelin receptor signalling in squamous cell carcinoma

SHUNSUKE ISHIMOTO1,2, KOICHIRO WADA1, NORIAKI TANAKA2, TADASHI YAMANISHI2, KOHJI ISHIHAMA2, TOMONAO AIKAWA2, MASAYA OKURA2, ATSUSHI NAKAJIMA3, MIKIHIKO KOGO2 and YOSHINORI KAMISAKI1

1Department of Pharmacology and 2The First Department of Oral and Maxillofacial Surgery, Graduate School of Dentistry, Osaka University, 1-8 Yamadaoka, Suita, Osaka 565-0871; 3Department of Gastroenterology, Yokohama City University School of Medicine, 3-9 Fuku-ura, Yokohama 236-0004, Japan

Received September 12, 2011; Accepted October 27, 2011

DOI: 10.3892/ijo.2011.1258

Abstract. Endothelin plays important roles in various physiological functions including vascular constriction. Recent studies reported that the endothelin receptors ETα and ETβ are highly expressed in lung and skin tumor tissues. In contrast, there are few reports on endothelin signalling in the proliferation of head and neck cancer. We found that both ETα and ETβ endothelin receptors were overexpressed in tumor cells of tongue cancer samples by immunohistochemistry. ETα and ETβ were expressed in cultured lingual and esophageal squamous cell carcinoma (SCCs) cell lines. When both cultured cell lines were treated with an ETα selective antagonist (BQ123) or an ETβ selective antagonist (BQ788), inhibition of cell growth was observed. Similar results were observed when SCCs were treated with specific siRNA for the suppression of ETα or ETβ. Furthermore, inhibition of the mitogen-activated protein (MAP) kinase pathway by the treatments with ET receptor antagonists and siRNA was also observed. These results indicate that endothelin signalling may, in part, play important roles in cell growth in SCCs through the MAP kinase pathway.

Introduction

Endothelin (ET) plays important roles on various physiological functions including vascular constriction (1-4). ET family comprises three isoforms, ET-1, ET-2, and ET-3, that bind to two receptor subtypes, endothelin A (ETα) and endothelin B (ETβ) receptors (1-4). Recent studies reported that ETα and ETβ were highly expressed on lung, colon and skin cancers (5-7). In addition, several reports suggested that ET-1 plays important roles in tumorigenesis, tumor progression, and metastasis (8-10). Thus, the ET receptors and their signalling pathways may be a therapeutic target in cancer therapy (11). However, little is known about the role of ET signalling on tumor cell proliferation of oral squamous cell carcinoma (SCC).

Human SCC is major neoplasm in esophagus or oral cavity and the incidence has recently been increasing (12-14). The optimal treatment for early carcinoma of oral cavity is surgical operation. However, overall survival remains largely unchanged (12-14). In addition, the decrease in quality of life (QOL) after wide excision of tongue is also important issue for patients. Therefore, different therapies are required. In our previous studies, we investigated the whole genome analysis using DNA microarray to find the potential target genes involved in tumor cell growth, and reported the critical role of several important molecules on the cell growth of SCCs (15-19). According to the results of DNA microarray, we found increased expression of ET receptor mRNA in cell lines of oral SCCs and the alteration of expression level on SCC growth (15,18,19). Therefore, we have examined whether ET receptors may be expressed in primary oral SCC tissues, and whether ET receptor-signalling may play a critical role of SCC growth. Our results imply a potentially important and novel role of ET function on SCC growth, and suggest that ET receptor-signalling might be useful target in the therapy of SCCs.

Materials and methods

Tissue samples. All of clinical studies were approved by the Ethics Committee of Osaka University Dental Hospital. Twenty-three samples of squamous cell carcinoma (SCC) located in the tongue were obtained from surgical resection tissue specimens at Osaka University Dental Hospital after informed consent was obtained. The patients, who received no preoperative therapy including chemotherapy and irradiation therapy, were randomly selected (Table I). The age range was 33-92 years (average: 62.0±13.9 years, mean ± SD).

Chemicals and antibodies. ET receptor specific antagonists, BQ123 for ETα and BQ788 for ETβ were purchased from Sigma-Aldrich Japan (Tokyo, Japan). Anti-ETα or ETβ polyclonal antibody was from Acris (Acris, Herford, Germany). Antibodies against Focal adhesion kinase (FAK), phosphorylated FAK,
phosphorylated MEK1/2, p44/42 MAPK (pErk1/2) phosphorylated p44/42 MAPK and anti-rabbit IgG (HRP-linked) for secondary antibody are from Cell Signalling Technologies (Beverly, MA). Cisplatin was from Wako Pure Chemical Industries, Ltd. (Osaka, Japan).

**Immunohistochemical staining of ET\textsubscript{A} and ET\textsubscript{B}**. The expression of ET\textsubscript{A} or ET\textsubscript{B} in tissues was detected by anti-ET\textsubscript{A} or ET\textsubscript{B} specific polyclonal antibody using standard immunohistochemical techniques on formalin-fixed and paraffin-embedded continuous sections. Incubation with anti-ET\textsubscript{A} or ET\textsubscript{B} polyclonal antibody was performed at 4°C for 16 h, then the sections were washed out. After the application with secondary antibody, theVectastain ABC kit (Vector Laboratories, Burlingame, CA) was used with a 3,3'-diaminobenzidine (DAB) substrate kit, according to the manufacturer's instructions. The staining endpoint was determined when the standard tissue sections were constantly stained to the intensity as described previously (18,19).

The intensity of the immunohistochemical staining with anti-ET\textsubscript{A} or ET\textsubscript{B} antibody was evaluated by scoring the staining reaction in four groups: (-), none/weak; (+), weak/moderate; (++), moderate/strong, and (+++), very strong cytoplasmic staining intensity, respectively (18,19). To check the reproducibility of the evaluation system concerning the immunohistochemical staining for the ET\textsubscript{A} and ET\textsubscript{B} proteins, another oral surgeon and pathologist who were unaware of the original assessment re-evaluated the results of staining according to the system above. Tumor areas were confirmed by both of the pathologist and surgeon under the microscopy. Non-tumor areas were selected, the comparatively normal areas were separated away from the tumor areas, and confirmed by the pathologist.

**Cell culture.** We used human oral SCC cell line (SAS) and human esophageal SCC cell line (KYSE70). SAS was established as tongue SCC and KYSE70 was established as esophageal SCC (15,16). SAS was maintained in DMEM containing 10% fetal bovine serum (FBS), and KYSE70 was maintained in DMEM containing 2% FBS at 37°C under 0.5% CO\textsubscript{2}. For cell growth experiment, cells were trypsinized and replated onto culture dishes (15-19).

| Case | Age/ Gender | Differentiation | ET\textsubscript{A} expression Tumor area | ET\textsubscript{B} expression Tumor area | ET\textsubscript{A} expression Non-tumor area | ET\textsubscript{B} expression Non-tumor area |
|------|-------------|-----------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|
| 1    | 71/F        | Well differentiated SCC | +++ | + | +++ | + |  |
| 2    | 57/M        | Well differentiated SCC | + | N/A | ++ | N/A |  |
| 3    | 69/M        | Well differentiated SCC | ++ | N/A | +++ | N/A |  |
| 4    | 64/M        | Well differentiated SCC | +++ | + | +++ | + |  |
| 5    | 46/F        | Well differentiated SCC | ++ | + | +++ | + |  |
| 6    | 61/M        | Well differentiated SCC | + | N/A | + | N/A |  |
| 7    | 48/M        | Well differentiated SCC | ++ | N/A | +++ | N/A |  |
| 8    | 72/M        | Well differentiated SCC | ++ | N/A | +++ | N/A |  |
| 9    | 79/M        | Well differentiated SCC | ++ | N/A | ++ | N/A |  |
| 10   | 68/M        | Moderately differentiated SCC | +++ | N/A | +++ | N/A |  |
| 11   | 64/M        | Moderately differentiated SCC | ++ | + | +++ | + |  |
| 12   | 58/F        | Moderately differentiated SCC | +++ | N/A | +++ | N/A |  |
| 13   | 92/F        | Moderately differentiated SCC | ++ | - | +++ | - |  |
| 14   | 86/F        | Moderately differentiated SCC | ++ | + | + | + |  |
| 15   | 57/M        | Moderately differentiated SCC | +++ | N/A | +++ | N/A |  |
| 16   | 62/M        | Moderately differentiated SCC | ++ | N/A | +++ | N/A |  |
| 17   | 52/F        | Poor-moderately differentiated SCC | ++ | N/A | ++ | N/A |  |
| 18   | 38/M        | Poorly differentiated SCC | + | - | ++ | + |  |
| 19   | 51/F        | Poorly differentiated SCC | ++ | - | ++ | + |  |
| 20   | 67/M        | Poorly differentiated SCC | ++ | N/A | ++ | N/A |  |
| 21   | 66/M        | Poorly differentiated SCC | ++ | N/A | +++ | N/A |  |
| 22   | 65/M        | Poorly differentiated SCC | ++ | N/A | +++ | N/A |  |
| 23   | 33/M        | Poorly differentiated SCC | ++ | - | +++ | + |  |

Expression of ET\textsubscript{A} or ET\textsubscript{B} by immunohistochemical staining in tumor and non-tumor area is scored and expressed as (-) to (+++). N/A, not applicable.
BQ788 for ETα for 24 and 48 h in culture medium. Then, cell viability was measured 24 and 48 h after the treatment using Countess Automated Cell Counter (Invitrogen, Eugene, OR). The inhibition of cell growth was compared to vehicle-treated control.

RNA interference approach. SAS and KYSE70 were trypsinized and resuspended in DMEM without FBS, and the cells were separated approximately 1x10⁶ cells for each dish. The ETα and ETβ-specific siRNA (Stealth siRNA) were purchased from Invitrogen Japan (Tokyo, Japan). The sequence of the sense strand of ETα-siRNA is 5'-UUUGAUGUGGCAUGAGCAACAGG-3', and anti-sense is 5'-CCUGUAUGCUAUGCCACAUCAAA-3', respectively. For the transfection, ETα-siRNA (40 nM) or negative control (40 nM Stealth RNAi Negative Control Duplexes, Invitrogen Japan Inc.) solution was added to DMEM medium containing Lipofectamine RNAiMax (Invitrogen Japan) and allowed to incubate for 20 min at room temperature to create the transfection mixture. The transfection mixture was then added to the cells at the indicated final concentration of siRNA. Twenty-four hours after the transfection, the medium was changed to DMEM containing 10% FBS for SAS and 2% FBS for KYSE70. Then, viable cell number was measured 24 and 48 h after the medium change using Countess Automated Cell Counter. The cell growth was expressed as the percentage to that of vehicle control.
**Western blot analysis.** Adherent or suspended cells were washed in PBS, and cell extracts were prepared by lysing cells in lysis buffer. The proteins were separated by electrophoresis using 10% SDS-PAGE, and transferred to nitrocellulose membrane (Millipore, Bedford, MA). Detection of proteins was performed by each polyclonal antibody and visualized by using the ECL detection kit (Amersham, London, UK) following the manufacturer's suggested procedure.

**Combination of ET\(_A\), ET\(_B\)-siRNA and anti-tumor drug.** Combined treatment of ET\(_A\), ET\(_B\)-siRNA with anti-tumor drug, cisplatin, was performed. Briefly, after the low concentration of ET\(_A\) or ET\(_B\)-siRNA (20 nM) treatment, 2.5 μM of cisplatin that was a concentration slightly effective on cell growth inhibition was treated for 48 h. Cell growth was measured by Countess Automated Cell Counter and expressed as percentage.

**Statistical analysis.** All results are expressed as mean ± SEM. Statistical comparisons were made using the Student-t test or Scheffe's method after analysis of variances (ANOVA). The results were considered significantly different at P<0.05.

**Results**

**Lingual SCCs in tumor tissues express ET\(_A\) and ET\(_B\).** Lingual SCC primary tissues were stained using anti-ET\(_A\) or anti-ET\(_B\) specific antibody, respectively. Positive staining of ET\(_A\) was

Figure 2. Effects of ET receptor antagonists on SCC cell growth. (A and B) Effect of ET\(_A\) antagonist, BQ123 or ET\(_B\) antagonist, BQ788 on cell growth of SAS. Typical images (A) and cell growth rate (B). 48 and 72 h after the start of treatment, viable cell number was counted and cell growth rate was expressed. Each column represents the percentage of cell growth (mean ± SEM from 4-5 independent experiments) compared to vehicle control (black column, PBS). Error bars represent standard deviations. *P<0.01, **P<0.05 vs. negative control. (C and D) Effect of ET\(_A\) antagonist, BQ123 or ET\(_B\) antagonist, BQ788 on cell growth of KYSE70.
observed in tumor area (Fig. 1A, right). In contrast, none of staining of ET\(_A\) was observed in non-tumor area in the same tissue section (Fig. 1A, left). Similar staining pattern was also observed in other tumor tissue sections (Table I). Statistically significance of the ET\(_A\) expression between tumor and non-tumor area was observed (Fig. 1B). In addition, positive staining of ET\(_B\) in tumor area, but not non-tumor area, was also observed in the same tissue section (Fig. 1C). Statistical significance of the ET\(_B\) expression between tumor and non-tumor areas was also observed (Fig. 1D and Table I). These results are similar to that of ET\(_A\). Good correlation between ET\(_A\) and ET\(_B\) expression was observed (Fig. 1E).

**ET receptor antagonists suppress cell growth of lingual and esophageal SCC.** According to the data of ET receptor expression in SCCs, we hypothesized that ET receptor-signalling might play an important role on the cell growth of SCCs. To investigate the hypothesis, we used ET receptor antagonists, BQ123 for ET\(_A\) and BQ788 for ET\(_B\). As shown in Fig. 2A and B, ET receptor antagonists, BQ123 and BQ788 suppressed the cell growth of

---

**Figure 3.** Effects of ET receptor knockdown on the cell growth of SCCs treated with ET\(_A\)- or ET\(_B\)-siRNA. (A and B) Effects of ET\(_A\)-siRNA or ET\(_B\)-siRNA on cell growth of SAS. Typical images (A) and cell growth rate (B). Cells were transfected the siRNA (40 nM) for 24 h and cultured for additional 48 h, followed by viable cell counting. Each value represents the percentage of cell growth compared with vehicle (non-siRNA) control from 4-7 independent experiments. White column represents the growth of cells transfected with ET\(_A\) (left panel) or ET\(_B\) (right panel)-siRNA and black column represents that of cells transfected with negative control-siRNA, respectively. Error bars represent standard deviations. *P<0.01, **P<0.05 vs. negative control. (C and D) Effects of ET\(_A\)-siRNA and ET\(_B\)-siRNA on cell growth of KYSE70. Typical photos (C) and cell growth rate (D). Cells were transfected the siRNA (40 nM) for 24 h and cultured for additional 48 h, followed by viable cell counting. Each value represents the percentage of cell growth compared with vehicle (non-siRNA) control from 4 independent experiments. White column represents the growth of cells transfected with ET\(_A\) (left panel) or ET\(_B\) (right panel)-siRNA and black column represents that of cells transfected with negative control-siRNA, respectively. Error bars represent standard deviations. *P<0.01, **P<0.05 vs. negative control.
lingual SCC cell line, SAS. The suppression by the antagonists was concentration- and time-dependent (data not shown).

In addition to the results of growth suppression of lingual SCC by the inhibition of ET receptors, both antagonists also suppressed the cell growth of esophageal SCC cell line, KYSE70 (Fig. 2C and D). These results indicate that ET receptor-signalling is required for the growth of SCCs.

**ETα and ETβ-siRNA suppress cell growth of lingual and esophageal SCC.** To clarify the exact function of ET receptors on the growth of SCCs, we used small interfering RNA (siRNA) for ETα and ETβ. ETα and ETβ-siRNA effectively decreased the ET receptor protein levels in SCCs. The inhibition of cell growth on SAS was clearly observed when ETα or ETβ was knocked down by the treatment with siRNA (Fig. 3A and B). Similar suppression of cell growth by the knockdown of ETα or ETβ was also observed when esophageal SCC cell line, KYSE70 was treated with siRNA for ETα or ETβ (Fig. 3C and D). These results clearly indicate that ET receptor-signalling is required for the growth of SCCs.

**Investigation of potential mechanisms.** We next investigated the mechanisms of inhibition of cell growth induced by the suppression of ET receptor-signalling. Western blot analysis showed the expression of ETα and ETβ proteins on the lingual SCC cell line SAS (Fig. 4A). Although the specific antagonists blocked the ETα or ETβ signalling, no alterations of receptor protein expression levels were observed (Fig. 4A). In contrast, blockade of ET receptor-signalling by the treatment with antagonists caused the suppression of phosphorylation of MEK and Erk (mitogen-activated protein kinase), the important members of MAPK pathway (Fig. 4B). In addition, similar suppression of MAPK pathway by knockdown of ET receptors was observed when SAS and KYSE70 were treated with ETα or ETβ-siRNA.

Figure 4. Involvement of MAPK pathway on ET receptor-signalling of SCC growth. (A) A Western blot analysis showing ETα or ETβ expression in SAS which were pre-treated with ETα antagonist, BQ123, or ETβ antagonist, BQ788. GAPDH is standard for equivalent application. No alteration was observed. (B) Suppression of MAPK pathway by ET receptor antagonists. SAS was treated with ETα antagonist, BQ123, or ETβ antagonist, BQ788, then the phosphorylation of Mek (p-MEK) or Erk (p-Erk) was detected for Western blot analysis. (C) Western blot analysis for expression of p-MEK and p-Erk by the treatment with ETα or ETβ-siRNA on SAS. Cells were treated with ETα or ETβ-siRNA (20 and 40 nM), negative control siRNA and vehicle (Veh). Samples were collected for 24 h after the treatment. GAPDH was used to evaluate equivalent loading. (D) Western blot analysis for expression of p-MEK and p-Erk by the treatment with ETα or ETβ-siRNA on SAS. Cells were treated with ETα or ETβ-siRNA (20 and 40 nM), negative control siRNA and vehicle (Veh). Samples were collected 24 h after the treatment. GAPDH was used to evaluate equivalent loading.
These results indicate the involvement of MAPK pathway on the ET receptor-signalling mediated cell growth of SCCs.

In contrast, no inhibition of phosphorylation of focal adhesion kinase (FAK), a 125 kDa non-receptor tyrosine kinase (20,21), by the suppression of ET receptor signalling was observed (data not shown).

We also investigated the effect of blockade of ET receptor-signalling on expression of integrins such as integrin α5 and β1 (22,23). However, no alterations of integrin α5 and β1 expressions were observed (data not shown). These results suggest that the cell growth suppression of SCCs by the knockdown or blockade of ET receptors is mediated through the direct inhibition of MAPK signalling pathway.

Combination therapy of ETα or ETβ-siRNA and anti-tumor drugs. Reduction of dosage of anti-tumor drugs for cancer chemotherapy is clinically important to minimize the side effects, although the complete tumor cell death is required. Combined treatment of ETβ-siRNA (20 nM) with anti-tumor drug, cisplatin (2.5 μM), drastically inhibited the cell growth of SAS in comparison to that in each single treatment (Fig. 5A). Similar results were also observed in the combined treatment of ETα-siRNA (20 nM) with cisplatin (data not shown). These results indicate that combination therapy of ETα or ETβ-siRNA and ordinal anti-tumor drugs may be a novel and useful therapy for SCCs.

Discussion

There have been several reports on the expression of ET receptors in various human cancers (5-7), and it is considered to be the relationship between ET receptor-signalling and tumor cell growth. There are, however, few reports on the evaluation and investigation of the exact role of ET receptor-signalling using human SCC tissues and cultured cell lines of oral and esophageal carcinomas.

In the present study, using an immunohistochemical method, we demonstrated significantly higher levels of expression of ETα and ETβ protein in human lingual cancer
tissues than in non-tumor areas in the same tissue samples. Similar results were also observed on the cultured SCC cell lines such as SAS, lingual SCC, and KYSE70, esophageal SCC. These results indicate the involvement of ET receptor-signalling on SCC growth. Furthermore, we showed that the suppression of ET receptor protein by siRNA or the blockade by antagonists caused the inhibition of SCC growth. In our experimental conditions, both the treatment with \( \text{ET}_A \) and \( \text{ET}_B \) antagonists and siRNA strongly inhibited the cell growth of SCCs. These results strongly suggest the important role for ET receptor-signalling in SCC cell survival. In fact, recent reports strongly indicated the involvement of ET and its receptor on oral cancer (24,25). In addition, it was also reported that suppression of endothelin-converting enzyme-1 caused the inhibition of SCC proliferation (26). Our results, together with those reports, strongly suggest the importance of ET synthesis and its receptor-signalling pathway on oral SCC proliferation.

It is reported that phosphorylation of FAK is involved in the inhibition of apoptosis and promote cell growth in SCC cell lines (15,18). FAK is a 125 kDa non-receptor tyrosine kinase and an important regulator of cell survival, invasion, migration, and cell cycle progression (15,18,20,21). FAK is functionally important in transducing intracellular messages that are associated with growth factor signalling (15,18,20,21,27). The intracellular messages link p-FAK at Tyr\(^{925} \) to signalling pathways that activate MAPK cascades. In our present study, however, the inhibition of phosphorylation of FAK in SCCs treated with ET antagonists and siRNAs was not observed. In contrast, the inhibition of the phosphorylation of MEK and Erk by the treatment with ET antagonists and siRNAs was clearly observed. These results indicate that the inhibition of MAPK pathway by the suppression of ET receptor-signalling is due to the direct inhibition of MAPK pathway, but not through FAK pathway (Fig 5B). Several reports have indicated the coupling of ET receptor-signalling and MAPK pathway (28,29). Our results agree with those reports and indicate that the mechanisms of the inhibition of cell growth by ET receptor-siRNAs and antagonists are, in part, due to the inhibition of MAPK pathway.

Reduction of dosage of anti-tumor drugs for cancer chemotherapy is clinically important to minimize the side effects, although the complete tumor cell death is required. Combined treatment of low concentration of ET receptor-siRNA (20 nM) with low concentration of anti-tumor drug, cisplatin (2.5 \( \mu \)M), drastically inhibited the cell growth of SAS in comparison to that in each single treatment. Cisplatin is extensively characterized as DNA damaging agent and the cytotoxicity of cisplatin is attributed to the ability to form inter and intra-strand nuclear DNA crosslinks (30,31). In contrast, inhibition of cell growth by ET receptor-siRNAs presented in our study was mainly due to the direct inhibition of MAPK pathway. Therefore, those two pathways on growth inhibition are different. This difference of mechanisms between ET receptor-siRNA and cisplatin may lead to show synergistic effect on the inhibition of tumor cell growth (Fig 5A and B). Our results indicate that the decrease in ET receptor levels in SCCs that strongly express ET receptors increases the sensitivity against chemotherapy, and that the siRNA for ET receptors combined with anti-tumor drugs might be a useful therapy to reduce the dosage of anti-tumor drugs.

In summary, we showed the overexpression of \( \text{ET}_A \) and \( \text{ET}_B \), in tumor cells of human primary lingual SCC tissues and cultured SCC cell lines, and suggest a potentially important role for ET receptor-signalling on the cell growth of human SCCs.

**Acknowledgements**

This study was supported in part by grants (21592357 to K.W., 20390471 to Y.K., and 21390535 to M.K.) from the Japanese Society for the Promotion of Science, and was supported by The Osaka Medical Research foundation for Intractable Diseases.

**References**

1. Yanagisawa M, Kurihara H, Kimura S, et al: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332: 411-415, 1988.
2. Inoue A, Yanagisawa M, Kimura S, et al: The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA 86: 2863-2867, 1989.
3. Davenport AP: International union of pharmacology. XXIX. Update on endothelin receptor nomenclature. Pharmacol Rev 54: 219-226, 2002.
4. Kusserow H and Unger T: Vasoactive peptides, their receptors and drug development. Basic Clin Pharmacol Toxicol 94: 5-12, 2004.
5. Ahmed SI, Thompson J, Coulson JM and Woll PJ: Studies on the expression of endothelin, its receptor subtypes, and converting enzymes in lung cancer and in human bronchial epithelium. Am J Respir Cell Mol Biol 22: 422-431, 2000.
6. Asham E, Shankar A, Loizidou M, et al: Increased endothelin-1 in colorectal cancer and reduction of tumor growth by ET(A) receptor antagonist. Br J Cancer 85: 1759-1763, 2001.
7. Zhang Y, Tang L, Su M, et al: Expression of endothelins and their receptors in nonmelanoma skin cancers. J Cutan Med Surg 10: 269-276, 2006.
8. Spinella F, Rosano L, DiCastro V, Natali PG and Bagnato A: Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor-1 alpha in ovarian carcinoma cells. J Biol Chem 277: 27850-27855, 2002.
9. Wulfing P, Kersting C, Tio J, et al: Endothelin-1, endothelin-A-, and endothelin-B-receptor expression is correlated with vascular endothelial growth factor expression and angiogenesis in breast cancer. Clin Cancer Res 10: 2393-2400, 2004.
10. Boldrin L, Gisfredi S, et al: Expression of endothelin-1 is related to poor prognosis in non-small cell lung carcinomas. Eur J Cancer 41: 2828-2835, 2005.
11. Kandalaft LE, Facciabene A, Buckanovich RJ and Coukos G: Endothelin B receptor, a new target in cancer immune therapy. Clin Cancer Res 15: 4521-4528, 2009.
12. Goepfert H: Squamous cell carcinoma of the head and neck: past progress and future promise. CA Cancer J Clin 48: 195-198, 1998.
13. Okura M, Hiranuma T, Adachi T, et al: Induction chemotherapy is associated with an increase in the incidence of locoregional recurrence in patients with carcinoma of the oral cavity: results from a single institution. Cancer 82: 804-815, 1998.
14. Prince S and Bailey BM: Squamous carcinoma of the tongue: review. Br J Oral Maxillofac Surg 37: 164-174, 1999.
15. Masuda T, Wada K, Nakajima A, et al: Critical role of peroxisome proliferator-activated receptor \( \gamma \) on anokis and invasion of squamous cell carcinomas. Clin Cancer Res 11: 4012-4021, 2005.
16. Takahashi H, Fujita K, Fujisawa T, et al: Inhibition of peroxisome proliferator-activated receptor gamma activity in esophageal carcinoma cells results in a drastic decrease of invasive properties. Cancer Sci 97: 854-860, 2006.
17. Ishida H, Wada K, Masuda T, et al: Critical role of estrogen receptor on anokis and invasion of squamous cell carcinoma. Cancer Sci 98: 636-643, 2007.
18. Nagata M, Wada K, Nakajima A, et al: Role of myeloid cell leukemia-1 on cell growth of squamous cell carcinoma. J Pharmacol Sci 110: 344-353, 2009.
19. Kusayama M, Wada K, Nagata M, et al: Critical role of aquaporin 3 on growth of human esophageal and oral squamous cell carcinoma. Cancer Sci 102: 1128-1136, 2011.
20. Chen HC, Appeddu PA, Parsons JT, Hildebrand JD, Schaller MD and Guan JL: Interaction of focal adhesion kinase with cytoskeletal protein talin. J Biol Chem 270: 16995-16999, 1995.
21. Sieg DJ, Hauck CR, Ilic D, et al: FAK integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol 2: 249-256, 2000.
22. Zhang Z, Vuori K, Reed JC and Ruoslahti E: The alpha 5 beta 1 integrin supports survival of cells on fibronectin and up-regulates Bel-2 expression. Proc Natl Acad Sci USA 92: 6161-6165, 1995.
23. Yamada KM and Geiger B: Molecular interactions in cell adhesion complexes. Curr Opin Cell Biol 9: 76-85, 1997.
24. Hoffman RR, Yurgel LS and Campos MM: Endothelins and their receptors as biological markers for oral cancer. Oral Oncol 46: 644-647, 2010.
25. Hoffman RR, Yurgel LS and Campos MM: Evaluation of salivary endothelin-1 levels in oral squamous cell carcinoma and oral leukoplakia. Regulatory Peptide 166: 55-58, 2011.
26. Awano S, Dawson LA, Hunter AR, Turner AJ and Usmani BA: Endothelin system in oral squamous carcinoma cells: Specific siRNA targeting of ECE-1 blocks cell proliferation. Int J Cancer 118: 1645-1652, 2006.
27. Frish SM and Francis H: Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 124: 619-626, 1994.
28. Bogoyevitch MA, Glennon PE, Andersson MB, et al: Endothelin-1 and fibroblast growth factors stimulate the mitogen-activated protein kinase signalling cascade in cardiac myocytes. J Biol Chem 269: 11190-11196, 1994.
29. Cramer H, Schmenger K, Heinrich K, et al: Coupling of endothelin receptors to the ERK/MAP kinase pathway. Eur J Biochem 268: 5449-5459, 2001.
30. Meyers M, Hwang A, Wagner MW and Boothman DA: Role of DNA mismatch repair in apoptotic responses to therapeutic agents. Environ Mol Mutagen 44: 249-264, 2004.
31. Psyrri A and Fountzilas G: Advances in the treatment of locally advanced non-nasopharyngeal squamous cell carcinoma of the head and neck region. Med Oncol 23: 1-15, 2006.